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Abstract: Background: Lymphoplasmacytic lymphoma and plasma cell myeloma are two B cell lymphoproliferative 
neoplasms derived from mature B-lymphocytes in different differentiation stages. The coexistence of these two 
tumors in the same patient is exceedingly rare and can be difficult to diagnose. Case presentation: A 76-year-old 
male presented with a pathologic fracture after a fall. Radiography showed a lytic lesion in the pelvis. Serum immu-
nofixation showed distinct IgM kappa and IgA kappa monoclonal protein bands. Bone marrow examination revealed 
aggregates of small, mature lymphoid cells with admixed plasma cells. Immunohistochemical studies and flow 
cytometric analysis showed the lymphoid cells were CD10-/CD5- kappa restricted monoclonal B cells. The plasma 
cells were monoclonal with kappa light chain restriction. The majority of plasma cells were positive for IgA and cy-
clin D1 with a few plasma cells positive for IgM. Additional studies showed the presence of both a positive MYD88 
L265P mutation and a CCND1/IGH fusion. A diagnosis of concomitant lymphoplasmacytic lymphoma and plasma 
cell myeloma was rendered. Conclusion: Concomitant lymphoplasmacytic lymphoma and plasma cell myeloma can 
be rarely encountered and is diagnostic challenging. It is commonly associated with biclonal monoclonal proteins. 
This case demonstrates the importance of a comprehensive work-up in the diagnosis of this disease combination 
and highlights the diagnostic role of MYD88 mutation study. 
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Introduction
Lymphoplasmacytic lymphoma (LPL) and plas-
ma cell myeloma (PCM) and are two B cell 
lymphoproliferative neoplasms that arise from 
mature B lymphocytes in different stages of 
differentiation. LPL is composed of neoplastic 
lymphocytes, plasmacytoid cells and plasma 
cells, and is usually associated with an IgM 
monoclonal paraprotein [1]. Waldenstrom mac-
roglobulinemia (WM) is an IgM producing LPL 
involving bone marrow [2]. In the past, the 
diagnosis of LPL/WM was based on exclud- 
ing other B cell lymphoproliferative disorders. 
The main differential includes other small ma- 
ture B cell lymphomas with plasmacytic dif- 
ferentiation, primarily marginal zone lympho- 
ma and plasma cell neoplasms in certain cir-
cumstances. Recently, the MYD88 L265P mu- 
tation was found to be a relatively sensitive 
and specific molecular abnormality in LPL/WM.
Plasma cell myelomas (PCM) and related plas-
ma cell neoplasms are immunoglobulin pro- 
ducing terminally differentiated monoclonal B 
cells. PCM shows various cytogenetic abnor-
malities, such as translocation, hyperploidy and 
hypoploidy, which are often associated with dif-
ferent clinical and prognostic features. PCM 
can present with various clinical/laboratory ab- 
normalities, including hypercalcemia, renal de- 
ficiency, anemia, bone lesions and increased 
M-protein in serum/urine. Plasma cell neoplas- 
ms producing IgG or IgA monoclonal proteins 
are relatively common whereas those produc-
ing IgM monoclonal proteins are rare. While the 
diagnosis of PCM is commonly straightforward, 
cases of PCM with atypical features may be dif-
ficult to distinguish from B cell lymphoma with 
plasmacytic differentiation, particularly LPL.
The coexistence of LPL and PCM in the same 
patient is extremely rare and has been previ-
ously reported in five patients only. The diag- 
nosis can be very challenging due to many si- 
milarities between plasma cell neoplasms and 
LPL/WM at the histomorphologic level. We re- 
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port a case of concomitant LPL and PCM that 
illustrates this diagnostic conundrum and the 
diagnostic role of ancillary studies.  
Case presentation
The patient was a 76-year-old retired Caucasian 
male who presented with right hip pain after a 
With a clinical suspicion of myeloma, bone mar-
row evaluation of the right posterior iliac crest 
was performed. Histomorphological examina-
tion (Figure 3) revealed a hypercellular bone 
marrow with frequent lymphoplasmacytic ag- 
gregates consisting small mature lymphocytes 
and lesser number of plasma cells (Figure 3A 
and 3B). Morphologically, the plasma cells have 
Figure 1. Serum protein electrophoresis and serum immunofixation assay. 
SPEP shows three protein bands, one of which is quite faint. On the corre-
sponding serum immunofixation study, these bands correspond to two IgA 
kappa, and one IgM kappa monoclonal proteins, respectively. Arrows point 
to the protein bands. Serum protein electrophoresis was performed on the 
Helena Laboratories SPIFE 3000 (Beaumont, TX) using Helena Laboratories 
reagents and antisera.
Figure 2. Radiographic study showing right acetabular fracture and lytic le-
sion (circled by yellow arrow).
trivial fall. X-ray showed an 
acetabular fracture of the 
right pelvis. Physical exami- 
nation showed no lympha- 
denopathy or organomegaly. 
The patient’s past medical 
history was unremarkable. 
Laboratory workup showed 
the following: (1) a mild nor-
mocytic anemia, 11.7 g/dL 
[reference interval, 13.4-17.0 
g/dL], with normal white cell 
and platelet counts; (2) decre- 
ased total protein, 5.9 g/dL 
[reference interval, 6.3-8.2 
g/dL] and albumin, 2.5 g/dL 
[reference interval, 3.5-5.0 g/
dL]; (3) elevation of serum 
IgA, 728 mg/dL [reference 
interval, 60-400 mg/dL] and 
IgM, 904 mg/dL [reference 
interval, 60-300 mg/dL] with 
decreased serum IgG, 318 
mg/dL [reference interval, 
700-1500 mg/dL]. Immuno- 
globulin quantitation was per-
formed on the Beckman 
Coulter Immage 800 (Brea, 
CA). Serum protein electro-
phoresis (SPEP) showed three 
distinct monoclonal protein 
bands (0.08 g/dL, 0.28 g/dL 
and 0.57 g/dL) in the gamma 
region. Serum immunofixation 
electrophoresis (IFE) confirm- 
ed three monoclonal protein 
bands: an IgM kappa mono-
clonal protein band and two 
IgA kappa monoclonal protein 
bands (Figure 1). Radiographs 
revealed one large lytic lesion 
within the right acetabulum 
and ischium with destruction 
of the medial wall of the ace-
tabulum (Figure 2).
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two distinct cytologic appearances (Figure 3C 
and 3D). One group of plasma cells had the 
classical plasma cell morphology that makes 
them indistinguishable from the typical nor- 
mal/reactive plasma cells. The other group of 
plasma cells showed ample homogeneous 
eosinophilic or clear cytoplasm with very dense 
nuclei, mimicking epithelioid histiocytes. These 
histiocytoid plasma cells were more abundant 
than those having a classical plasma cell appea- 
rance.
Immunohistochemical studies revealed the 
small lymphocytes within the aggregates were 
primarily CD20 (Figure 3E) and PAX-5 positive 
B cells. CD138 showed that plasma cells com-
prised about 5-10% of the cell population in 
the bone marrow (Figure 3F) and were kappa 
restricted (Figure 3G). The histiocytoid plasma 
cells were positive for IgA (Figure 3H); the plas-
ma cells with classical morphology were posi-
tive for IgM (Figure 3I). Additional immunohisto-
chemical stains indicated that the histiocytoid 
Figure 3. Histologic and immunohistochemical findings in the marrow. A. (100×) and B. (400×) Frequent lympho-
plasmacytic aggregates in marrow clot section; C. (clot section) and D. (bone marrow aspirate) Red and yellow ar-
rowheads indicating the two plasma cell morphologies in a plasma cell aggregate; E. B-cell aggregates highlighted 
by CD20; F. Plasma cell aggregates/clusters highlighted by CD138; G. Kappa light restriction indicated by kappa and 
lambda staining pattern; H. Histiocytoid plasma cells positive for IgA; I. IgM highlighting plasma cells with classical 
morphology; J. Expression of cyclin D1 in plasma cells; K. Colocalization of IgA (red, cytoplasm) and cyclin D1 (brown, 
nucleus); L. Lack of colocalization of IgM (red) and cyclin D1 (brown).
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plasma cells were positive for cyclin D1 (Figure 
3J). Double immunohistochemical staining for 
IgA and cyclin D1 (Figure 3K) vs IgM and cyclin 
D1 (Figure 3L) demonstrated co-localization of 
IgA and cyclinD1, confirming that only the IgA 
positive histiocytoid plasma cells were express-
ing cyclin D1.  
Flow cytometric analysis of bone marrow dem-
onstrated a monoclonal B cell population with 
kappa light chain restriction. These B cells were 
positive for CD19 and CD20 and negative for 
CD5 and CD10 (Figure 4). CD23 was also nega-
tive. In addition, a monotypic plasma cell popu-
lation positive for CD38, CD138 and cytoplas-
mic kappa light chain (Figure 5) was identified.
Karyotypic analysis performed on the bone 
marrow aspirates showed normal male karyo-
type. Fluorescence in situ hybridization (FISH) 
was positive for t(11;14) CCND1/IGH fusion 
gene (Figure 6). Sequencing study of myeloid 
differentiation primary response gene 88 (MY- 
D88) was positive for the L265P mutation. The 
diagnosis of a kappa restricted lymphoplas- 
macytic lymphoma with concomitant kappa re- 
stricted plasma cell myeloma was rendered.
The patient responded well to a bortezomib 
based regimen and has since been in hemato-
logic remission. 
Discussion
LPL/WM is an uncommon lymphoproliferative 
disorder with an incidence of 3.4/106 among 
men and 1.7/106 among women [3]. LPL/WM 
generally has an indolent course with median 
survival of 5-10 years. The proposed cell of ori-
gin is a post-germinal center B-cell that lacks 
ongoing somatic mutation [4]. There is no spe-
cific immunophenotypic or cytogenetic abnor-
mality in LPL/WM. Deletion of the long arm of 
chromosome 6 (6q-) is the most common ab- 
normality, occurring in more than 40% of the 
cases [5].  LPL does not show translocation of 
CCND1, MALT1, BCL2 or BCL6 [1]. In 2012, 
Treon et al. [6] described a MYD88 L265P so- 
matic mutation in LPL/WM patients. MYD88 
functions as an adapter molecule that is used 
by most toll-like receptors (TLR) to facilitate 
signaling. Treon et al. [6] reported that the MY- 
D88 L265P mutation was the most common 
gene mutation in LPL, identified in 91% of LPL 
patients. By contrast, PCM, including IgM pro-
ducing myeloma, is negative for MYD88 L265P 
mutation. The majority of small mature B cell 
lymphomas are also negative for this mutation 
except for 10-15% of splenic marginal zone lym-
phoma cases and 4% of chronic lymphocytic 
leukemia cases. Notably, MYD88 L265P muta-
tion is preferentially identified in non-germinal 
Figure 4. A monoclonal CD20+, CD19+, CD5-, CD10- and kappa light chain restricted B cell population.
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center type diffuse large B cell lymphoma and 
is usually associated with poorer prognosis. 
These findings support the clinical utility of 
MYD88 L265P mutational analysis in the dif-
ferential diagnosis of LPL, PCM and other low 
grade B cell lymphomas.
PCM and its related plasma cell neoplasms 
are composed of terminally differentiated B 
cells that secrete monoclonal immunoglobu-
lins. However, monoclonal immunoglobulin can 
be also occasionally produced by B cell lym- 
phoma. If bone marrow evaluation demonstra- 
tes a monoclonal plasma cell population with 
polyclonal B cells, a diagnosis of plasma cell 
neoplasm is indicated. If a monoclonal B cell 
population with polyclonal plasma cell popula-
tion is detected, a diagnosis of B cell lympho- 
ma rather than plasma cell neoplasm is enter-
tained. If both a monoclonal B cell population 
and a monoclonal plasma cell population with 
the same light chain restriction are identified, 
a diagnosis of B cell lymphoma with plasma-
cytic differentiation is most likely to be ren-
dered. In such cases, however, exclusion of a 
coexisting but separate plasma cell neoplasm 
based solely on morphologic evaluation is es- 
sentially impossible.
The metachronous or synchronous coexistence 
of LPL/WM with other hematolymphoid malig-
nancies is rare. In a study performed on 924 
patients with WM [7], only 17 patients (2.8%) 
were found to have concomitant hematologic 
malignancies. Out of these 17 patients, 13 pa- 
tients had diffuse large B cell lymphoma and 
the remaining 4 patients had therapy related 
acute myeloid leukemia. Reports in the litera-
Figure 5. A monotypic CD38+, CD138+, dim CD45+ and cytoplasmic kappa light chain restricted plasma cell popu-
lation.
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ture also include two cases of concomitant WM 
with Hodgkin lymphoma [8], one case of WM 
with renal MALT lymphoma [9] and one case of 
WM with chronic lymphocytic leukemia [10]. 
The association of LPL/WM and plasma cell 
neoplasms is extremely rare and has been re- 
ported in only five patients previously [11-15]. 
Table 1 shows the clinicopathological findings 
of these cases: two patients were male and 
three, female, with a median age of 73 years 
and presenting with non-specific symptoms 
that included fatigue, weakness and weight 
loss. Two patients had lytic lesions and two 
patients had lymphadenopathy and organo-
megaly. All five patients had monoclonal IgM 
proteins, with four having co-existing IgG mo- 
noclonal protein and one with a monoclonal 
IgA protein. Four patients had multiple myelo-
ma and one had a plasmacytoma of the oral 
cavity.
In addition, several reports have described two 
or more M spikes, including two patients in a 
series of three patients reported by Sanders et 
al. [15]; however, none of those patients show 
convincing evidence that these two monoclo- 
nal proteins were secreted by two disease pro-
cesses. For the patients in Table 1, evidence 
of biclonality relied heavily on morphologic and 
immunophenotypic evaluation. In addition to 
relying on morphologic features and immuno-
phenotypic evaluations, our case is the first 
one to use MYD88 to help establishing the 
biclonality of the disease.
nosis of small B cell lymphoma with plasma-
cytic differentiation would have been rendered 
due to the diagnostic difficulty of further differ-
entiating between marginal zone lymphoma 
and LPL/WM. Positive MYD88 L265P mutation 
result in the current case allowed us to give 
specific diagnosis of LPL/WM. However, an 
additional question was raised: is the mono-
typic plasma cell population in the bone mar-
row part of LPL/WM spectrum or a separate 
plasma cell neoplasm?  Lytic bone lesions, as 
seen in the current case, is not typical for LPL/
WM. Additionally, the presence of two parapro-
teins (IgM and IgA) in the serum, raises suspi-
cion for biclonality. Further morphologic and 
immunohistochemical evaluation demonstrat-
ed two distinct plasma cell morphhologies. The 
histiocytoid plasma cells express IgA and the 
plasma cells with classical morphology express 
IgM, in line with two disease processes. Finally, 
the presence of t(11;14) detected by FISH and 
positivity for cyclin D1 by immunohistochemical 
stain clinched the diagnosis of a concomitant 
plasma cell myeloma. 
Conclusion
Concomitant LPL and PCM is rarely encoun-
tered and is associated with biclonal monoclo-
nal protein. To arrive at the correct diagnosis, 
the integration of the clinical, morphologic, im- 
munophenotypic and cytogenetic work-up is 
necessary. When LPL is being considered in 
the differential diagnosis, the MYD88 muta-
tional assay is of value.
Figure 6. FISH of bone marrow aspirate with CCND1/IGH translocation us-
ing the Abbott Vysis (Abbott Park, IL) LSI CCND1/IGH dual color dual fusion 
translocation probe. The IGH probe is green and the CCND1 probe is red. 
Normal cells show two separate green and red signals (left). The abnormal 
cells show fused yellow signal (right).
The diagnosis of current ca- 
se was very challenging. The 
presence of both monoclonal 
B cell population and plas- 
ma cell population with same 
light chain restriction sug-
gests a diagnosis of either 
B cell lymphoma with plas- 
ma cell differentiation or B 
cell lymphoma with coexist- 
ing plasma cell neoplasm. 
The B cells in the bone mar-
row are small and mature by 
morphology and CD5-/CD10- 
by immunophenotyping. The 
main differential diagnosis in- 
cludes marginal zone lym- 
phoma and LPL/WM. In the 
past, a more descriptive diag-
Co-existing lymphoplasmacytic lymphoma and myeloma
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